Cambridge, UK, 26 August 2020: Axol Bioscience, a biotechnology company specializing in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, today announced the appointment of Liam Taylor as CEO. Liam will guide the growth of the Company, and will focus on maximizing the potential of the team, and its iPSC (induced pluripotent stem cell) technologies, products and services.

    Liam is a highly experienced senior executive with extensive knowledge of running commercial, operations, finance and innovation teams in the diagnostic, pharma and life science sector, both in the UK and US. Most recently he was CFO and then Managing Director of BBI Solutions, during which time the business’ annual revenues grew from £23M to over £52M, driven by organic growth and strategic acquisitions, which broadened the Company’s product and service offerings.

    Dr Jonathan Milner, Chairman, Axol Bioscience, said: “The Board is delighted to appoint Liam as Axol’s new CEO. His wealth of experience and comprehensive knowledge of the pharma and life science sector will be invaluable in unlocking the full potential of the Company.”

    Liam Taylor, CEO, Axol Bioscience, added: “The progress achieved at Axol Bioscience in developing high quality and consistent iPSCs has been impressive, and I am excited to be joining at an exciting point in the Company’s development where we will be working to scale up operations to support the rapidly growing biotech and pharmaceutical markets, to support increases in efficiency within drug screening and discovery.”

    For further information about Axol Bioscience’s leadership team, please visit: https://www.axolbio.com/page/meet-the-team.

    ENDS


    Notes to Editors

    Dr Jonathan Milner, Chairman, Axol Bioscience

    Liam Taylor, CEO, Axol Bioscience

    For a high-resolution image please contact Zyme Communications.

    For further information please contact:

    Axol Bioscience
    John Burgess
    Tel: +44 (0) 1223 751051
    Email: j.burgess@axolbio.com

    Zyme Communications
    Michelle Ricketts
    Tel: +44 (0) 7789 053885
    Email: michelle.ricketts@zymecommunications.com

    To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

    About Axol Bioscience www.axolbio.com

    Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

    Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.

    The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.

    Follow Axol Bioscience on Twitter @axolbio and LinkedIn Axol Bioscience Ltd.


    Share this post:
     

    Chief Operating Officer appointed at Axol Bioscience